ID   KHM-5M
AC   CVCL_2975
SY   KHM/5M; KHM5M
DR   BioSample; SAMN03470813
DR   BioSample; SAMN03470887
DR   cancercelllines; CVCL_2975
DR   CCRID; 3101HUMSCSP549
DR   CGH-DB; 57-1
DR   CLS; 305148
DR   Cosmic; 2054085
DR   FANTOM5_SSTAR; 10776-110G2
DR   JCRB; JCRB0148
DR   JCRB; NIHS0194
DR   Wikidata; Q54899907
RX   PubMed=1728417;
RX   PubMed=16924234;
RX   PubMed=23833040;
RX   PubMed=25877200;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Doubling time: 27 hours (Note=Lot 09272002) (JCRB=JCRB0148).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptomics; Microarray.
CC   Discontinued: JCRB; NIHS0194; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): JCRB=JCRB0148; PubMed=25877200; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11.3,12.3 (JCRB=JCRB0148)
ST   CSF1PO: 12,13 (PubMed=25877200; PubMed=30737244)
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D18S51: 16,19
ST   D19S433: 14
ST   D21S11: 28,31
ST   D2S1338: 19,23
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 22,23
ST   Penta D: 9,11
ST   Penta E: 11,18
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 28
//
RX   PubMed=1728417;
RA   Yoshida M., Matsuzaki H., Sakata K., Takeya M., Kato K., Mizushima S.,
RA   Kawakita M., Takatsuki K.;
RT   "Neutrophil chemotactic factors produced by a cell line from thyroid
RT   carcinoma.";
RL   Cancer Res. 52:464-469(1992).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//